Genomes and Genes
Affiliation: Harvard University
- Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levelsC Jesser
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
Br J Cancer 99:1743-7. 2008..Meta-analysis of 12 studies of rs266882 and overall prostate cancer risk was null...
- Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen eraKe Zu
Affiliations of authors Department of Nutrition KZ, MJS, Eg, Department of Epidemiology LM, MJS, Eg, and Department of Biostatistics BAR, Harvard School of Public Health, Boston, MA Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA LM, Bar, MJS, EG Department of Internal Medicine, The Ohio State University, Columbus, OH SKC Department of Pathology, Dana Farber Cancer Institute, Boston, MA ML
J Natl Cancer Inst 106:djt430. 2014....
- Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancerMichelangelo Fiorentino
Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
Lab Invest 88:1340-8. 2008..001, Spearman's rho=0.33). We propose that cytoplasmic stabilization of beta-catenin through palmitoylation of Wnt-1 and subsequent activation of the pathway is a potential mechanism of FASN oncogenicity in prostate cancer...
- Immunohistochemical expression of BRCA1 and lethal prostate cancerMichelangelo Fiorentino
Department of Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Res 70:3136-9. 2010..6; 95% confidence interval, 2.4-8.7). These findings strengthen the hypothesis that BRCA1 plays a role in cell cycle control and show that BRCA1 is a marker of clinical prostate cancer prognosis. Cancer Res; 70(8); 3136-9. (c)2010 AACR...
- Evaluation of 8q24 and 17q risk loci and prostate cancer mortalityKathryn L Penney
Department of Epidemiology, Harvard School of Public Health, Harvard University, Cambridge, Massachusetts, USA
Clin Cancer Res 15:3223-30. 2009..We investigated whether the 8q24 and 17q risk variants are associated with clinical variables as well as prostate cancer mortality...
- ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancerChangmeng Cai
Hematology Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
J Clin Invest 123:1109-22. 2013..Together, these results demonstrate that ERG redirects AR to a set of genes including SOX9 that are not normally androgen stimulated, and identify SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive PCa...
- Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysisJing Ma
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Lancet Oncol 9:1039-47. 2008..We assessed the effect of prediagnostic BMI and plasma C-peptide concentration (reflecting insulin secretion) on prostate cancer-specific mortality after diagnosis...
- SMAD4-dependent barrier constrains prostate cancer growth and metastatic progressionZhihu Ding
Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Nature 470:269-73. 2011..This model-informed progression analysis, together with genetic, functional and translational studies, establishes SMAD4 as a key regulator of PCA progression in mice and humans...
- Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancerMark A Preston
Department of Urology, Massachusetts General Hospital Harvard School of Public Health, Boston, MA, USA
BJU Int 111:514-7. 2013..This evidence-based medicine article addresses the clinical utility of prostate MRI for preoperative staging. Based on a common patient scenario, a guide to calculating the probability of extraprostatic extension is provided...
- Shiftwork and prostate-specific antigen in the National Health and Nutrition Examination SurveyErin E Flynn-Evans
Division of Sleep Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
J Natl Cancer Inst 105:1292-7. 2013..Our aim was to investigate the relationship between shiftwork and prostate-specific antigen (PSA) test obtained as part of the National Health and Nutrition Examination Survey (NHANES) study...
- Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific deathMark A Rubin
Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005..This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer...
- Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancerToshiro Migita
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Natl Cancer Inst 101:519-32. 2009..Overexpression of the fatty acid synthase (FASN) gene has been implicated in prostate carcinogenesis. We sought to directly assess the oncogenic potential of FASN...
- Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 69:5568-74. 2009..These data will help to direct the future study of this risk locus...
- Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer ProgressionLorelei Mucci; Fiscal Year: 2009....
- Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer ProgressionLorelei Mucci; Fiscal Year: 2010....